Drug Profile
Research programme: single domain antibodies - Argenta/Domantis
Alternative Names: Single domain antibodies research programme - Argenta/DomantisLatest Information Update: 20 Jul 2010
Price :
$50
*
At a glance
- Originator Argenta Discovery; Domantis
- Class Antibodies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Chronic obstructive pulmonary disease; Respiratory tract disorders
Most Recent Events
- 07 Jan 2007 Domantis has been acquired by GlaxoSmithKline
- 10 Nov 2006 Preclinical development is still ongoing
- 26 Oct 2004 Preclinical trials in Chronic obstructive pulmonary disease in United Kingdom (Inhalation)